CRSP240802C53000
- 3.52
- -0.48-12.00%
CRISPR Therapeutics Newsroom
TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30
CRISPR Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)
CRISPR Therapeutics Analyst Ratings
Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Stifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating
Buy Rating Affirmed for Crispr Therapeutics AG on Strong Pipeline and Financial Health
Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $67
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating
CRISPR Therapeutics Analyst Ratings
Crispr Therapeutics AG: A Balanced Hold Rating Amidst Pipeline Progress and Financial Caution
Barclays Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)
Strong Buy Rating for Crispr Therapeutics AG Amid Innovative Advances and Global Expansion
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Crispr Therapeutics AG (CRSP)
Buy Rating on Crispr Therapeutics: Anticipated Clinical Catalysts and Undervalued Autoimmune Prospects
Buy Rating on Crispr Therapeutics AG Backed by Exa-cel's Precision and Favorable Safety Profile